ADIPOSE DERIVED STEM CELL THERAPY MARKET ANALYSIS

Adipose Derived Stem Cell Therapy Market, by Cell Type (Allogeneic Stem Cells and Autologous Stem Cells), by Product Type (Cell lines and Culture Media), by Application (Therapeutic Application, Research Application, and Other Applications), by End User (Cell & Tissue Banks, Biotechnology & Pharmaceutical Organizations, and Research & Academic Organizations), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022-2028

To Be Published : Nov 2024
Code : CMI2357
Formats :
Excel and PDF
Industry : Biotechnology

Regional Analysis

Adipose Derived Stem Cell Therapy Market Regional Analysis

North America is expected to hold a dominant position in the global adipose derived stem cell therapy market and account the largest market share during the forecast period, owing to high presence of key players in the region, which are engaged in research & development activities and implementing in-organic growth strategies such as acquisition and collaboration to increase its market presence.

For instance, in December 2017, Mesoblast Limited made exclusive license agreement with TiGenix NV, through which Mesoblast granted TiGenix an exclusive access to certain of its patents to support global commercialization of Cx601, adipose derived mesenchymal stem cell product, for the local treatment of fistulae.

By Region